Economic Evaluation of First-Line Treatments for Metastatic Renal Cell Carcinoma: A Cost-Effectiveness Analysis in A Health Resource–Limited Setting

• Bin Wu,

  Affiliation Clinical Outcomes and Economics Group, Department of pharmacy, Renji Hospital, affiliated with the School of Medicine, Shanghai Jiaotong University, Shanghai, People's Republic of China

  ⨯
• Baijun Dong,

  Affiliation Department of Urology, Renji Hospital, affiliated with the School of Medicine, Shanghai Jiaotong University, Shanghai, People's Republic of China

  ⨯
• Yuejuan Xu,

  Affiliation Department of Oncology, the Second Hospital of Nanjing, affiliated to Medical School of South East University, Nanjing, People's Republic of China

  ⨯
• Qiang Zhang,

  Affiliation Department of Oncology, Shanghai Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China

  ⨯
• Jinfang Shen,

  Affiliation Clinical Outcomes and Economics Group, Department of pharmacy, Renji Hospital, affiliated with the School of Medicine, Shanghai Jiaotong University, Shanghai, People's Republic of China

  ⨯
• Huafeng Chen,

  Affiliation Clinical Outcomes and Economics Group, Department of pharmacy, Renji Hospital, affiliated with the School of Medicine, Shanghai Jiaotong University, Shanghai, People's Republic of China

  ⨯
• Wei Xue

  * E-mail: xwurosjtu@yeah.net

  Affiliation Department of Urology, Renji Hospital, affiliated with the School of Medicine, Shanghai Jiaotong University, Shanghai, People's Republic of China

  ⨯